Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
Summary by Charleston Gazette-Mail
82 Articles
82 Articles
All
Left
10
Center
23
Right
5
Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
SHANGHAI, June 15, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4 inhibitor, for the treatment of Hepatocellular Carcinoma…
Coverage Details
Total News Sources82
Leaning Left10Leaning Right5Center23Last UpdatedBias Distribution61% Center
Bias Distribution
- 61% of the sources are Center
61% Center
L 26%
C 61%
13%
Factuality
To view factuality data please Upgrade to Premium